Myos Corp (MYOS) 14.80 $MYOS
MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM)
Marketwire - Thu Sep 18, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research agreement with Human Metabolome Technologies America, Inc. ("HMT" . Founded in 2003, HMT is a global leader in the emerging fields of metabolomics and systems biology. HMT will apply their proprietary, state-of-the-art capillary electrophoresis-mass spectrometry (CE-MS) technologies to characterize the metabolomic profiles of plasma samples obtained from healthy male subjects who used either Fortetropin(TM) or placebo with the goal of identifying metabolites with pro-myogenic activity in the plasma samples of subjects who took Fortetropin as well as examining the effect on glucose and fat metabolism.
MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Marketwire - Thu Sep 04, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that Robert Ashton, M.D., Chief Medical Officer of MYOS, will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. Dr. Ashton is scheduled to present at 11:40 a.m. Eastern Time on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.
MYOS Corporation Reports 2014 Second Quarter Results
Marketwire - Thu Aug 14, 5:45AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today its financial results for the second quarter ended June 30, 2014. The Company also provided highlights of its recent progress and anticipated near-term research and development milestones for Fortetropin(TM), the first clinically proven natural myostatin inhibitor.
MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014
Marketwire - Thu Aug 07, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it will release its financial results for the second quarter ended June 30, 2014, before the market opens on Thursday, August 14, 2014.
MYOS Corporation Reports Additional Clinical Data on the Impact of Fortetropin on Lean Body Mass, Fat Mass and Muscle Size in Male Subjects
Marketwire - Wed Aug 06, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has published a white paper entitled "The Impact of Fortetropin on Muscle." The white paper provides additional results of its clinical trial designed to study the effects of Fortetropin(TM) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.
MYOS elects Douglas Weekes as chief commercial officer
M2 - Thu Jul 31, 5:49AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) reported on Wednesday that Douglas Weekes has been named as its chief commercial officer.
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
Marketwire - Wed Jul 30, 7:04AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed Douglas Weekes as Chief Commercial Officer. Mr. Weekes will lead the Company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin(TM). Positive clinical results have demonstrated that daily use of Fortetropin along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reduced inflammation. Mr. Weekes will lead the creation of several bionutrition products including bars, meal replacement formats and ready to drink beverages utilizing Fortetropin.
MYOS renews manufacturing and supply agreement of Fortetropin with DIL
M2 - Mon Jul 28, 6:19AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) said on Friday that it has extended its agreement for the continued manufacturing and supply of the first clinically proven natural myostatin inhibitor Fortetropin with Deutsches Institut fuer Lebensmitteltechnik e.V (DIL), the German Institute for Food Technologies.
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
Marketwire - Fri Jul 25, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL" , the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin(TM), the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
GlobeNewswire - Thu Jul 24, 7:41AM CDT
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 -
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects
Marketwire - Tue Jul 22, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin(TM) (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
Marketwire - Thu Jul 17, 6:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.
MYOS hires Dr. J. Craig Venter to board
M2 - Tue Jul 15, 5:06AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) revealed on Monday the addition of genomic pioneer, Dr. J. Craig Venter, Ph.D. to its board of directors.
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Marketwire - Mon Jul 14, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors.
MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
Marketwire - Wed Jul 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has received approval for the listing of its common stock on the NASDAQ Capital Market ("NASDAQ" . The common stock is expected to begin trading on the NASDAQ at market open on July 10, 2014 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9, 2014.
MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
Marketwire - Thu Jun 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview ("Worldview" .
MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
Marketwire - Tue Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA" with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations.
MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM)
Marketwire - Thu Sep 18, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research agreement with Human Metabolome Technologies America, Inc. ("HMT" . Founded in 2003, HMT is a global leader in the emerging fields of metabolomics and systems biology. HMT will apply their proprietary, state-of-the-art capillary electrophoresis-mass spectrometry (CE-MS) technologies to characterize the metabolomic profiles of plasma samples obtained from healthy male subjects who used either Fortetropin(TM) or placebo with the goal of identifying metabolites with pro-myogenic activity in the plasma samples of subjects who took Fortetropin as well as examining the effect on glucose and fat metabolism. MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Marketwire - Thu Sep 04, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that Robert Ashton, M.D., Chief Medical Officer of MYOS, will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. Dr. Ashton is scheduled to present at 11:40 a.m. Eastern Time on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City. MYOS Corporation Reports 2014 Second Quarter Results
Marketwire - Thu Aug 14, 5:45AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today its financial results for the second quarter ended June 30, 2014. The Company also provided highlights of its recent progress and anticipated near-term research and development milestones for Fortetropin(TM), the first clinically proven natural myostatin inhibitor. MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014
Marketwire - Thu Aug 07, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it will release its financial results for the second quarter ended June 30, 2014, before the market opens on Thursday, August 14, 2014. MYOS Corporation Reports Additional Clinical Data on the Impact of Fortetropin on Lean Body Mass, Fat Mass and Muscle Size in Male Subjects
Marketwire - Wed Aug 06, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has published a white paper entitled "The Impact of Fortetropin on Muscle." The white paper provides additional results of its clinical trial designed to study the effects of Fortetropin(TM) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa. MYOS elects Douglas Weekes as chief commercial officer
M2 - Thu Jul 31, 5:49AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) reported on Wednesday that Douglas Weekes has been named as its chief commercial officer.
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
Marketwire - Wed Jul 30, 7:04AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed Douglas Weekes as Chief Commercial Officer. Mr. Weekes will lead the Company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin(TM). Positive clinical results have demonstrated that daily use of Fortetropin along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reduced inflammation. Mr. Weekes will lead the creation of several bionutrition products including bars, meal replacement formats and ready to drink beverages utilizing Fortetropin. MYOS renews manufacturing and supply agreement of Fortetropin with DIL
M2 - Mon Jul 28, 6:19AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) said on Friday that it has extended its agreement for the continued manufacturing and supply of the first clinically proven natural myostatin inhibitor Fortetropin with Deutsches Institut fuer Lebensmitteltechnik e.V (DIL), the German Institute for Food Technologies.
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
Marketwire - Fri Jul 25, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL" , the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin(TM), the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today. Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
GlobeNewswire - Thu Jul 24, 7:41AM CDT
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 -
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects
Marketwire - Tue Jul 22, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin(TM) (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa. MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
Marketwire - Thu Jul 17, 6:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market. MYOS hires Dr. J. Craig Venter to board
M2 - Tue Jul 15, 5:06AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) revealed on Monday the addition of genomic pioneer, Dr. J. Craig Venter, Ph.D. to its board of directors.
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Marketwire - Mon Jul 14, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors. MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
Marketwire - Wed Jul 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has received approval for the listing of its common stock on the NASDAQ Capital Market ("NASDAQ" . The common stock is expected to begin trading on the NASDAQ at market open on July 10, 2014 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9, 2014. MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
Marketwire - Thu Jun 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview ("Worldview" . MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
Marketwire - Tue Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA" with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations. MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
